INTRODUCTION
Systemic juvenile idiopathic arthritis (sJIA) is classified as a subtype of juvenile idiopathic arthritis (JIA). The emerging consensus in pediatric rheumatology is that sJIA is not a 'classic' autoimmune disease, and therefore should be viewed as a distinct auto-inflammatory syndrome. Indeed, many clinical features of sJIA, such as fever, skin rashes and multisystem involvement, are similar to those seen in autoinflammatory syndromes, including familial Mediterranean fever (FMF) and cryopyrin-associated periodic syndrome (CAPS), a family of syndromes that includes Muckle Wells Syndrome; Neonatal-onset multisystem inflammatory disease; (NOMID) and FCAS. As in autoinflammatory syndromes, patients with sJIA are at risk for amyloidosis. The most beneficial therapeutic strategies in sJIA are aimed at neutralization of interleukin 1 and interleukin 6 rather than tumor necrosis factor alpha (TNFa), similar to CAPS.
There is a considerable body of work studying biomarkers in sJIA and CAPS. In this review, we focus on protein, cellular, mRNA and DNA markers in sJIA and similarities and differences in the molecular markers that have characterized these diseases. Is there a corresponding correlation between biomarkers in sJIA vs. biomarkers in CAPS?
Ferritin
In many inflammatory diseases, such as rheumatoid arthritis or lupus, ferritin levels rise moderately in parallel with other inflammatory acute phase reactants. In sJIA, however, ferritin levels may be extremely high and exceed 1000 ng/ml (normal range 7-140 ng/ml) [3, 4] and may be helpful in establishing the diagnosis of sJIA. The reasons for extreme hyperferritinemia in sJIA are not clear. The fact that many patients with active sJIA without macrophage activation syndrome (MAS) may still have ferritin levels exceeding 1000 ng/ml suggests that there may be a distinct inflammatory pathway unique to this disease. Consistently with this idea, ferritin has been shown to have both proinflammatory and anti-inflammatory properties and may serve as an important immunomodulator, although the exact pathogenic role of ferritin in these pathways still needs to be elucidated. When complicated by MAS, levels of ferritin are strikingly high [2] . Interestingly, in contrast to sJIA, no increase in ferritin levels was noted in a study of acute phase response in FMF [5, 6] . In addition, there are no reports of increased ferritin levels in CAPS. S100A8, S100A9 and S100A12 S100A8 (alias: MRP8), S100A9 (alias: MRP14) and S100A12 are typically secreted during activation of neutrophils and monocytes. S100A8/A9 form a complex that can serve as an endogenous toll-like receptor (TLR) agonist and trigger TLR4 signalling pathways [7] , leading to production of proinflammatory cytokines including interleukin 1-b. S100A12 can also activate human monocytes via TLR4 [8,9 & ]. Strikingly high levels of the calcium-binding proteins S100A8/A9 and S100A12 are characteristic of active sJIA and appear to distinguish sJIA from many other febrile illnesses, including systemic infection, various forms of leukemia and Kawasaki disease [10, 11] . Highly elevated S100 proteins are a feature that may be shared with other autoinflammatory syndromes such as FMF and CAPS [12] . S100A8/9 serum concentrations correlate closely in response to drug treatment and disease activity, and therefore might be an additional measurement for monitoring anti-inflammatory treatment of individual patients with sJIA. During clinically inactive disease, S100A8/9 serum concentrations are reported to be one of the first predictive biomarkers indicating subclinical disease activity. Serum levels of S100A8-S100A9 above 740 ng/ml predicted disease flares with 92% sensitivity and 88% specificity [13] .
Interleukin 18
Interleukin 18 is a unique cytokine in the interleukin 1 family and is constitutively present in keratinocytes, epithelial cells and blood monocytes. Interleukin 18 induces production of interferon gamma (IFNg) by natural killer (NK) cells and T cells as well as TNFa and chemokine secretion by macrophages. The most commonly used ELISA for circulating interleukin 18 detects about 100 pg/ml in the serum of healthy humans, whereas in diseases characterized by systemic inflammation, the levels are elevated several fold. CAPS is associated with elevated function of the NLRP3 inflammasome, which in turn results in the activation of caspase-1, cascading to increased levels of interleukin 18 [14] . Levels of interleukin 18 in Chronic infantile neurological, cutaneous and articular syndrome; (CINCA) patients, the most severe form of CAPS, are about three-fold higher than in healthy individuals (unpublished data). In sJIA, serum interleukin 18 levels are elevated out of proportion, compared with other cytokines in distinct contrast to CAPS as well as other diseases such as rheumatoid arthritis, sepsis, and others. Particularly, when complicated by MAS, levels of circulating interleukin 18 can be elevated several more than 10-fold. Although levels of free interleukin 18 correlate strongly with underlying
KEY POINTS
Serum biomarkers, such as ferritin, interleukin 18 and S100 proteins, are specifically correlated with MAS, sJIA or CAPS, respectively.
The polarization status of peripheral blood monocytes in sJIA patients appears to correlate with disease activity, suggesting in part, an anti-inflammatory role.
Transcriptional profiling of peripheral blood mononuclear cells revealed common dysregulated transcripts and pathways, but also distinct differences between sJIA and CAPS patients.
MAS is a clinical complication of sJIA and other autoinflammatory or autoimmune diseases, which is characterized by a distinct serum biomarker profile. disease activity in sJIA and decrease with clinical remission, in many sJIA patients, it remains elevated even during remission, which may be predictive of upcoming flare of sJIA [15 & ]. In particular, the S100 proteins and the interleukin 18 protein markers seem to correlate particularly well with disease status of active vs. inactive disease [16 && ]. A list of protein markers observed in sJIA and CAPS is shown in Table 1 [2] [3] [4] [10] [11] [12] [17] [18] [19] [20] [21] [22] .
CELLULAR BIOMARKERS IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
The analysis of cellular biomarkers in sJIA patients, such as leukocyte subset composition and activation or differentiation state of these subsets, is scarce. Macaubas et al. [23, 24] provided recent reports on lymphocyte subsets comprising monocytes, dendritic cells, NK cells, a or b and g or d T cells and B cells in quiescent and active disease stages in sJIA patients. The authors reported that the relative abundance of T and B cells among the mononuclear cells appears lower in flaring sJIA patients, compared with age-matched healthy controls.
Two other studies assessed the frequency of Th1 and Th17 T cells in sJIA patients. Although Omoyinmi et al. [25] found an increased frequency of circulating Th1 and Th17 cells in sJIA patients, compared with age-matched controls and regardless of their sJIA status, Lasiglie et al. [26] did not find a difference in the frequency of Th17 cells in sJIA patients. In contrast, the latter study found that Th17 cells were more abundant in CAPS patients prior to treatment with an interleukin 1 antagonist.
Cells of the myeloid lineage appear to be the prominent players in sJIA, and Macaubas et al. [23] performed a more in-depth analysis of monocyte subsets. Although the abundance of CD14þ monocytes was significantly higher in patients experiencing flare vs. healthy controls of quiescent sJIA individuals, the relative abundance of 'conventional' CD14þþ monocytes or 'inflammatory' CD14þ CD16þ monocytes was not different between disease state and healthy controls. However, monocytes from sJIA patients, irrespective of disease state, expressed significantly higher levels of CD16 and CD14 than those from healthy controls. This finding was replicated in a subsequent study [24] that assessed the polarization state of the monocyte populations in sJIA patients with quiescent and active disease, respectively. CD16 is believed to be expressed by monocytes or macrophages that have a more inflammatory M1 phenotype, whereas CD14 is upregulated on monocytes that appear to have a more anti-inflammatory M2 gene expression profile [27] . The same study by Macaubas et al. [24] presented a more refined analysis for monocyte or macrophage surface markers indicative for M1 or M2 polarization. They reported increased expression of the prototypic M1 markers CD40 and CD80 on CD14þþCD16À and CD14þCD16þ monocyte population in patients with active disease, compared with blood monocytes from quiescent disease state or healthy controls. Intriguingly, 90% of the monocyte population with increased M1 markers in active disease also expressed the CD163 and CD209 surface markers that are associated with an M2 phenotype. Thereby, monocytes from patients in an active disease state appear to have a mixed phenotype, reflecting an inflammatory state and at the same time the induction of counterbalancing anti-inflammatory pathways. Another recent study [28] on cellular biomarkers within the RAndomized Placebo Phase study Of Rilonacept in the Treatment of sJIA; trial assessing rilonacept in sJIA reported a positive correlation between the expression of the M2-specific transcription factor Kruppel-like factor-4 with active disease, supporting the previous notion of an in-part anti-inflammatory phenotype of blood monocytes in active sJIA.
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release of mature interleukin 1b seems to be lower. This might be related to the partial polarization of the sJIA monocytes toward an anti-inflammatory M2 transcriptional program. Thus, monocytes may constitute a regulatory cell type in sJIA counteracting the action of inflammatory mediators, potentially secreted by other cell types, such as neutrophils, lymphocytes or endothelial cells. It remains to be seen whether this peculiar monocyte phenotype reflects a physiological response to inflammation orchestrated by a different cell type or an intrinsic physiological or genetic defect.
GENE EXPRESSION PROFILING
There are several publications that describe the gene expression profiling analysis of sJIA patients, usually in peripheral blood mononucleated cells (PBMCs) [4, [29] [30] [31] . In general, a majority of the differentially expressed genes in active sJIA appear to be upregulated rather than downregulated, when compared with either healthy controls or inactive disease [31] .
There is substantial evidence that interleukin 1 plays a major role via the disruption of innate immunity in systemic JIA [29, 32] . Genes involved in innate immune activation like the components of the interleukin 1, interleukin 18 and TLR signaling pathways are seen to be upregulated in sJIA relative to healthy controls. In addition, some genes comprising the interleukin 1 inflammasome are also upregulated, and there is also upregulation of several neutrophil-related transcripts [31, 33] . This concept is further substantiated by the fact that the response to anti-interleukin 1b, anti-interleukin 6 and anti-interleukin 1R therapies is relatively high in sJIA [33] [34] [35] . A list of genes differentially expressed in sJIA (from [29] ) can be found in the supplementary material, http://links.lww.com/ COR/A18 [29] . Comparison of the gene expression profiles of the various forms of JIA in PBMCs relative to healthy controls [30] showed the overexpression of several pathways, with sJIA having the maximum number of dysregulated genes, and therefore, pathways. Chief among these pathways were the interleukin 10 signaling and innate immunity pathways. However, NK cell, T cell and antigen-presentation pathways were downregulated in sJIA.
To determine what aspects of the gene expression changes in sJIA vs. controls are unique to sJIA, Allantaz et al. [29] compared differentially expressed genes in sJIA and in infectious diseases such as those caused by Staphylococcus aureus, Streptococcus pneumoniae and other infections using systemic lupus erythematosus (SLE) and pyogenic arthritis, pyoderma gangrenosum; syndrome as negative controls. The comparison of the gene expression profiles shows that about 88 transcripts were significantly and specifically dysregulated in sJIA. Applying more stringent cutoffs. A more stringent analysis, applying a p-value cutoff of P < 0.0001 identified 12 of the 88 genes as highly differentially expressed in sJIA compared with healthy controls, but not differentially expressed (P > 0.5) in all other disease groups compared with their respective controls sJIA patients from the others. Six of these genes have no known function, whereas the others are involved in various processes relating to transport, nuclear mRNA splicing, and others.
A comparison of the upregulated genes in sJIA with those in other inflammatory diseases shows the highest similarity between sJIA and CINCA (or NOMID) relative to SLE, polyarticular JIA and Kawasaki disease. Ogilvie et al. [31] reported that of the approximately 285 genes that are upregulated in sJIA, about 35 genes are seen to beupregulated in CINCA as well, followed by sJIA and Kawasaki disease with approximately 17 overlapping genes followed by much weaker overlap with SLE or polyarticular JIA. Conversely, analysis of the gene expression profiles of CAPS indicates a list of about 60 genes that are also upregulated in sJIA [36] . A list of differentially expressed genes in CAPS relative to healthy controls (from [37 & ]) can be found in the supplementary material, http://links.lww.com/ COR/A18.
Comparison of differentially expressed genes in CAPS [37 & ,38] to those in sJIA identified a list of common genes shown in Table 2 in more detail. One striking feature of this list of genes is that several of these genes are seen in immature cells. For example, ALAS2, a gene that is highly upregulated in both sJIA and CAPS, is an enzyme critical to heme synthesis and is very active in immature cells. Other examples include HB1, HB2, HBG and AQP9. Hematopoietic stem cells in the bone marrow give rise to two major progenitor cell lineages: myeloid and lymphoid progenitors (Fig. 1 ). Hinze et al. [36] noted that unusual cell populations such as early myeloid progenitors distinguish sJIA from other types of JIA and other febrile illnesses. They developed a 67-gene signature for erythropoiesis (supplementary material, http://links.lww.com/COR/A18 from [36] ). Our comparison of the list of genes shown in Table 2 shows that 17 of the 67 genes are seen to be highly upregulated in CAPS, whereas in sJIA, the enrichment of this erythropoietic signature is much higher ( Table 3 ) (it is to be noted that this signature was characterized on the basis of earlier work on the gene expression profiles in sJIA [4] , hence the high enrichment of genes differentially expressed in sJIA is to be expected). This gene signature enrichment could be a reflection of the severity of the inflammatory processes in these diseases, resulting in relatively higher populations of the immature and monomyelocytoid cells in both sJIA and CAPS PBMCs.
GENETIC MARKERS
There have been several studies in sJIA cohorts that attempt to find genetic risk factors for sJIA. Associations between gene variants encoding inflammasome-related proteins and sJIA have been reported in IL6, IL18 and the IL1 family of genes; most of these associations reached borderline significance [39] . Although in other JIA subtypes, many risk loci have been identified, the results in sJIA have been disappointing. In a recent genome-wide association meta-analysis, only a weak association was found with the 3 Mb interval that contains a range of genes involved in both innate and adaptive immunity including BTNL2. However, the general consensus in the field is that sJIA is a polygenic disease, and it is likely that further research could uncover alleles in additional genes that may contribute to inherited risk factors in sJIA. In CAPS, however, unlike sJIA, there is a clear link to gain of function mutations in NLRP3 [40] , which lead to constitutive interleukin 1b secretion. MAS, a life-threatening complication of sJIA, is caused by excessive activation and expansion of T cells and CD163þ hemophagocytic macrophages. Because of their highly activated status, these cells shed off some of their receptors including CD163 and IL2Ra chains. As a result, in MAS, serum levels of soluble CD163 and soluble IL2Ra chains appear to reflect the degree of activation and expansion of T cells and macrophages, respectively, and may serve as biologic markers that can help with the diagnosis and assessment of treatment responses [18] . Another potential MAS biomarker is neopterin, a catabolic product of guanosine triphosphate that is produced by IFN-stimulated macrophages. One recent report suggested that highly increased levels of neopterin could distinguish patients with MAS from the patients with active sJIA without MAS features [19] . Another recent report described significantly elevated levels of follistatin-like protein 1 in MAS, compared with a conventional sJIA flare [41 & ]. Rapidly increasing serum ferritin is a feature that raises the suspicion for MAS, but a significant proportion of sJIA patients without MAS features may have highly elevated levels of ferritin as well [4] . When the diagnosis of MAS is established, however, serum ferritin levels are traditionally used to gauge the response to treatment. There have been association studies [42, 43] in MAS patients in which variants in perforin and MUNC genes appear to associate with the propensity to develop MAS.
Another intriguing aspect of sJIA is the biphasic course of the disease. Typically, sJIA begins with a highly inflammatory febrile phase that in the ]. Therefore, one important direction of future research in sJIA is the identification of biomarkers that would distinguish the two phases.
One of the challenges in diseases such as sJIA is that the disease activity is still scored on the basis of a mixture of objective (such as presence of fever and a number of active joints) and subjective measures (physician's assessment score such as American College of Rheumatoly; or Disease activity score). In order to assess disease activity in a standardized manner, targeted studies aimed at the discovery of molecular markers predictive of disease state will simplify disease assessment and could lead to further discovery of markers predictive of disease flares, MAS as well as the ability to taper treatment for the patient when there is confidence that the patient has inactive disease. One or more of the markers described in this review could indeed be part of the biomarker solution that can assist the physician to determine when and how to initiate or stop treatment of sJIA in a patient.
CONCLUSION
A survey of biomarkers in sJIA and a comparison with known markers in CAPS show that in addition to shared clinical phenotypes, there are common molecular markers as well. In particular, protein markers, such as interleukin 18 and S100 proteins, are upregulated in both sJIA and CAPS. Gene expression profiling shows an upregulation of innate immunity pathways, which points to similar inflammatory processes driving both disease types. For example, there is a good correspondence between the elevated level of total interleukin 18 protein in serum and elevated transcript levels of interleukin 18. Similarly, we observe elevated levels of S100A8/9 and S100A12 both at the gene and the transcript level in sJIA and CAPS patients. Interestingly, upon comparison of the differentially regulated genes in the microarray data, an erythropoietic signature is shared between CAPS and sJIA, although to different extents. Cellular biomarker research on immune cells, in contrast, may provide more insight into disease pathophysiology of sJIA by assessing the physiological characteristics of blood leukocytes. There is no work published to date on cellular markers in CAPS. We can also point to some distinct differences as well, notably the much higher incidence of MAS in sJIA, which is a much rarer event for CAPS patients, resulting in higher levels of ferritin as well as other markers like CD163, in sJIA. Further research into the similarities and differences in the molecular background between sJIA and CAPS could potentially help clinicians design optimal treatment strategies.
